Solid Tumor Therapeutics

实体肿瘤治疗学摘要 实体肿瘤治疗(STT)的总体目标是开发新的治疗方法和策略 非血液系统恶性肿瘤的治疗和发展所需的诊断和生物标记工具 使它们的使用个性化。因此，STT直接支持MCC的使命、愿景和战略重点， 它优先利用MCC的发现，以最大限度地提高我们根据以下条件定制癌症护理计划的能力 每个病人的个人资料。STT的59名成员来自不同的学科，但它们是结合在一起的 他们在实体肿瘤生物学和治疗方面的共同研究兴趣。为了反映这一点，成员来自 16个系和4所学校。2017年，计划成员在癌症方面的总支出为2230万美元(直接成本) 资金问题。1300万美元(直接成本)是同行评审的资金，其中600万美元(46%)来自NCI，390万美元(30%)是 来自其他NIH来源的300万美元(23%)来自其他同行审查机构。在项目期间， 成员撰写了1662份癌症相关出版物，其中255份(15%)是计划内出版物，295份(18%)是计划内出版物 是跨计划的，485人(29%)与来自NCI指定的其他癌症的研究人员合作 中锋。STT成员还领导了的早期研究员发起试验(IITs)，其中包括翻译20个 MCC通过26个IITs向临床提供的科学发现，在2008年间比2个此类IITs增加了13倍- 2012年。STT治疗IITs的应计收益增加了218%，从223(2008-2012年)增加到709(2013-2017)。STT的 具体目标是：1)确定肿瘤的脆弱性、机制和有针对性的改变；2)开发新的 治疗方法和输送系统的分类；3)开发检测肿瘤和确定肿瘤的新技术 地理、微环境和可利用的代谢和信号缺陷；以及4)建立临床 新疗法和基因组驱动的治疗策略的好处。贯穿各领域的主题是：a)免疫 肿瘤学；B)癌症干细胞，以及C)针对患者的精确治疗。STT由医学博士Ezra Cohen共同领导， 头颈部癌症和免疫肿瘤学发现的临床应用方面的专家；以及Jeremy 里奇，医学博士，理工学院硕士，MBA，他的职业生涯专注于癌症干细胞和脑瘤。他们的高度集成 努力促进STT杰出研究人员之间的合作，他们是各自领域的领导者，并已 超凡生产力的记录。

SOLID TUMOR THERAPEUTICS ABSTRACT The overall goal of Solid Tumor Therapeutics (STT) is to develop novel therapeutics and strategies for the treatment of non-hematologic malignancies and to advance the diagnostic and biomarker tools needed to individualize their use. As a result, STT directly supports the mission, vision, and strategic priorities of MCC, which has prioritized exploiting MCC’s discoveries to maximize our ability to tailor cancer care plans based on each patient’s personal profile. The 59 members of STT come from diverse disciplines but are joined together by their shared research interest in solid tumor biology and treatment. Reflecting this, members are drawn from 16 departments and 4 schools. In 2017, program members had a total of $22.3M (direct costs) in cancer-focused funding. $13.0M (direct costs) is peer-reviewed funding, of which $6.0M (46%) was from NCI, $3.9M (30%) was from other NIH sources, and $3.0M (23%) was from other peer-reviewed agencies. During the project period, members authored 1662 cancer-relevant publications, of which 255 (15%) were intra-programmatic, 295 (18%) were inter-programmatic, and 485 (29%) were collaborative with investigators from other NCI-designated cancer centers. STT members also led 64 early phase investigator-initiated trials (IITs), which include translation of 20 of MCC’s scientific discoveries to the clinic through 26 IITs, a 13-fold increase over 2 such IITs between 2008- 2012. Accrual to STT treatment IITs increased by 218%, from 223 (2008-2012) to 709 (2013-2017). STT’s specific aims are to: 1) Identify tumor vulnerabilities, mechanisms, and targetable alterations; 2) Develop new classes of therapeutics and delivery systems; 3) Develop novel technologies to detect tumors and define tumor geography, microenvironment, and exploitable metabolic and signaling defects; and 4) Establish the clinical benefit of novel therapeutics and genome-driven treatment strategies. The cross-cutting themes are: A) Immune Oncology; B) Cancer Stem Cells, and C) Patient-specific Precision Therapy. STT is co-led by Ezra Cohen, MD, an expert in head and neck cancer and the clinical application of immune oncology discoveries; and Jeremy Rich, MD, MHS, MBA, whose career has focused on cancer stem cells and brain tumors. Their highly integrated efforts foster collaboration among the outstanding investigators in STT, who are leaders in their fields and have track records of extraordinary productivity.